Novel Immunotherapy and Chemotherapy in Patients with Ovarian Cancer

Robert Wenham, MD, MS, FACOG, FACS, a gynecologic oncologist and chair of the Gynecologic Oncology Program at Moffitt Cancer Center, discusses novel immunotherapy combinations for the treatment of patients with ovarian cancer.

In the recent interview with OncLive^®, Dr. Wenham shared the rationale behind combining immune checkpoint inhibitors with chemotherapy is to not only kill cells through cytotoxic activity that increases the amount of antigen exposure, but also chemically debulking tumors. With less tumor, it is possible that cell energy will also be decreased, Wenham notes.

With PARP inhibitors, while repairing DNA, it is possible to inhibit the PARP enzyme and increase the number of DNA replication errors, which will then increase the number of antigens. Cytotoxicity would then be increased, due to increased antigen exposure, which makes the combination of PARP inhibitors and checkpoint inhibitors attractive, Wenham concludes.

Moffitt has a team of GYN cancer specialists at the forefront of cancer research, who are regularly developing new therapies and screening methods to effectively detect and treat GYN cancers.

To learn more about the Gynecologic Oncology program or to refer a patient to Moffitt, complete our online form or contact a physician liaison for assistance or support. 

To read more on this subject, please click here.